{
    "2020-11-02": [
        [
            {
                "time": "",
                "original_text": "刘格菘第二！年内四只翻倍基金，他竟独占其三",
                "features": {
                    "keywords": [
                        "刘格菘",
                        "翻倍基金",
                        "基金经理"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "基金",
                        "投资"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "【中金固收·信用】新发降温，二级市场走弱—中资美元债周报",
                "features": {
                    "keywords": [
                        "中金固收",
                        "新发降温",
                        "二级市场",
                        "中资美元债"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "债券",
                        "金融市场"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "",
                "original_text": "迈瑞、恒瑞、泰格、石药、华兰生物……上市药企投资价值大PK，你最PICK谁？",
                "features": {
                    "keywords": [
                        "迈瑞",
                        "恒瑞",
                        "泰格",
                        "石药",
                        "华兰生物",
                        "投资价值"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "麦格理：升药明康德（02359）目标价9%至152.27元 评级“跑赢大市”",
                "features": {
                    "keywords": [
                        "麦格理",
                        "药明康德",
                        "目标价",
                        "跑赢大市"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "明日下午3点！乘风破浪——新型生物技术时代下生物药临床前的生物分析策略 | 生物分析系列(六)",
                "features": {
                    "keywords": [
                        "生物技术",
                        "生物药",
                        "临床前",
                        "生物分析"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "生物科技",
                        "医药"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "",
                "original_text": "疫情影响逐渐消退，关注高成长龙头+细分冠军--医药生物上市公司2020年三季报小结",
                "features": {
                    "keywords": [
                        "疫情",
                        "高成长龙头",
                        "细分冠军",
                        "三季报"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "",
                "original_text": "【浙商医药|三季报】创新药研发高景气有望持续，看好CDMO业绩加速",
                "features": {
                    "keywords": [
                        "浙商医药",
                        "创新药",
                        "CDMO",
                        "业绩加速",
                        "三季报"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药",
                        "生物科技"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            }
        ]
    ]
}